Research analysts at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research note issued on Tuesday. The firm set a “hold” rating on the stock.
Separately, HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of Oncternal Therapeutics in a research note on Friday, May 31st.
Get Our Latest Stock Report on ONCT
Oncternal Therapeutics Stock Up 6.1 %
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($2.83) earnings per share for the quarter, topping the consensus estimate of ($2.88) by $0.05. The firm had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.18 million. Oncternal Therapeutics had a negative return on equity of 107.67% and a negative net margin of 3,160.73%. During the same quarter in the previous year, the business earned ($4.00) earnings per share. As a group, sell-side analysts anticipate that Oncternal Therapeutics will post -10.78 EPS for the current year.
Insider Activity
In other Oncternal Therapeutics news, Director Robert James Wills acquired 3,086 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were purchased at an average price of $8.96 per share, with a total value of $27,650.56. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $89,600. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.20% of the company’s stock.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC bought a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned about 0.94% of Oncternal Therapeutics as of its most recent filing with the Securities & Exchange Commission. 16.05% of the stock is owned by institutional investors and hedge funds.
Oncternal Therapeutics Company Profile
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Read More
- Five stocks we like better than Oncternal Therapeutics
- 10 Best Airline Stocks to Buy
- Ollie’s Bargain Outlet Stock Won’t be a Bargain Much Longer
- Insider Trades May Not Tell You What You Think
- CrowdStrike’s Earnings: Consolidation and AI-Driven Growth
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 Options Strategies to Protect Your Stocks in a Falling Market
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.